Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial.
Gabriel N. Hortobagyi
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Allan Lipton
Honoraria - Novartis
Research Funding - Novartis
Expert Testimony - Novartis
Helen K. Chew
No relevant relationships to disclose
William John Gradishar
No relevant relationships to disclose
Nicholas P. Sauter
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Ramon W. Mohanlal
Employment or Leadership Position - Novartis
Ming Zheng
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Beth McGrain
Employment or Leadership Position - Novartis
Catherine Van Poznak
Consultant or Advisory Role - Novartis
Research Funding - Novartis